Cancer Invasion and Metastasis

项目摘要/摘要 癌症侵袭和转移计划(CIM)是Sidney Kimmel计划中的一个新计划 综合癌症中心(SKCCC)CIM的推出是为了阐明和瞄准驱动机制 转移，因为转移是患者预后的主要驱动因素。该计划由高度 有成就的基础科学家与工程师和转化型内科科学家合作。这个 共同负责人是Andrew Ewald博士(基础，专注于侵袭)；Ashani Weeraratna，博士(基础，肿瘤) 关注微环境)；以及Phuoc Tran，医学博士，博士(关注基础/临床，复发性疾病)。CIM是 由来自三所学校的42名成员(31名正式成员和11名准成员)和16名成员组成 约翰斯·霍普金斯大学的系。教职员工与全校的四个T-32培训补助金有关联 医学院、公共卫生学院和工程学院。直接与癌症相关的同龄人- 审查后的资金为1410万美元，其中830万美元来自国家癌症研究所。总人数 计划成员发表的出版物有768篇，其中129篇(16.8%)是计划内的，412篇(53.8%)是计划间的 方案和487个(63.4%)有外部协作。在这些出版物中，20.6%是在以下期刊上发表的 在具有影响因子的期刊中，影响因子&gt；10%和5.7%。该方案的目标是：目标1： 阐明调控单个和集体癌细胞运动的分子和细胞机制 使用尖端模型和工具入侵器官部位。目标2：定义癌症的调节 通过肿瘤微环境的细胞、分子和力学特征发挥作用。调查人员的目标是 并干扰癌细胞和促进转移的微环境之间的串扰 生理相关模型(例如，器官模型、3D皮肤重建、细胞衍生基质、人源化 动物模型)。目标3：从细胞和组织角度确定和阻断癌症复发的根本原因 分子水平靶向肿瘤治疗成功的障碍，包括治疗抵抗、肿瘤 休眠和反复发作的疾病。跨这些目标的研究成功关键是由SKCCC共享的 资源(肿瘤学、组织和影像服务、实验和计算基因组学、流量/质量 细胞学和技术发展、质谱学、分子成像和多组学)。 计划成员领导一项P01赠款，以了解治疗耐药的微环境调节和 黑色素瘤的转移，以及整合了物理科学和翻译视角的U54 了解癌症的侵袭。成员还参与三个孢子(前列腺、胃肠道、头和颈部)和六个 MPI U01奖励。

PROJECT SUMMARY/ABSTRACT The Cancer Invasion and Metastasis Program (CIM) is a new Program within the Sidney Kimmel Comprehensive Cancer Center (SKCCC). CIM was launched to elucidate and target the mechanisms driving metastasis, as metastasis is the major driver of patient outcomes. The Program consists of highly accomplished basic scientists working collaboratively with engineers and translational physician-scientists. The Co-Leaders are Andrew Ewald, Ph.D. (basic, invasion focused); Ashani Weeraratna, Ph.D. (basic, tumor microenvironment focused); and Phuoc Tran, M.D., Ph.D (basic/clinical, recurrent disease focused). CIM is comprised of 42 Members (31 Full Members and eleven Associate Members) from three schools and 16 departments at Johns Hopkins University. Faculty are affiliated with four T-32 training grants across the School of Medicine, School of Public Health, and School of Engineering. The total direct cancer-relevant peer- reviewed funding is $14.1 million, with $8.3 million from the National Cancer Institute. The total number of publications by Program members is 768, of which 129 (16.8%) are Intra-Programmatic, 412 (53.8%) are Inter- Programmatic and 487 (63.4%) have external collaborations. Of these publications, 20.6% are in journals with impact factors >10 and 5.7% in journals with impact factors >25. The Aims of the Program are: Aim 1: To elucidate the molecular and cellular mechanisms regulating individual and collective cancer cell motility and invasion across organ sites using cutting-edge models and tools. Aim 2: To define the regulation of cancer function by the cellular, molecular and mechanical features of the tumor microenvironment. Investigators target and disrupt the crosstalk between the cancer cell and the metastasis-promoting microenvironment using physiologically relevant models (e.g., organoids, 3D skin reconstruction, cell-derived matrices, humanized animal models). Aim 3: To determine and disrupt the underlying cause of recurrent cancer at the cellular and molecular level by targeting barriers to therapeutic success in cancer, including therapy resistance, tumor dormancy and recurrent disease. Research success across these aims is critically enabled by SKCCC Shared Resources (Oncology Tissue and Imaging Services, Experimental and Computational Genomics, Flow/Mass Cytometry and Technology Development, and Mass Spectrometry Molecular Imaging and Multi-Omics). Program members lead a P01 grant to understand microenvironmental regulation of therapy resistance and metastasis in melanoma, and a U54 that integrates physical science and translational perspectives to understand cancer invasion. Members also participate in three SPOREs (Prostate, GI, Head and Neck) and six MPI U01 grants.